Untitled

Crohn's disease can be unpredictable, and many patients wonder whether newer biologic options might give them a better chance at lasting relief. Recent data from a head‑to‑head study called SEQUENCE offers fresh insight into two widely used biologics - risankizumab (Skyrizi) and ustekinumab (Stelara). Understanding what the trial found, how it fits with existing treatment pathways, and what it might mean for you can help you have a more informed conversation with your gastroenterology team. Why this matters

Crohn's disease often requires a step‑wise approach, starting with conventional medicines and moving to biologic therapies when symptoms persist. Both risankizumab and ustekinumab belong to a class of drugs that target specific proteins in the immune system, but they act on slightly different parts of the pathway. The SEQUENCE trial is one of the few studies that directly compared the two agents in patients with moderate‑to‑severe disease, offering a clearer picture of how each drug performs under similar conditions. What the SEQUENCE trial showed

The SEQUENCE trial enrolled adults with active Crohn's disease who had not responded adequately to conventional therapy. Participants were randomly assigned to receive either risankizumab or ustekinumab, with treatment continuing for 48 weeks. The primary endpoint was endoscopic remission, defined as the absence of visible ulcers on colonoscopy - a marker that many clinicians associate with better long‑term outcomes.

• At week 48, about 32 % of patients on risankizumab achieved endoscopic remission.
• In the ustekinumab group, roughly 16 % reached the same endpoint.

While these numbers suggest that risankizumab may lead to remission in a higher proportion of patients, the trial also reported variability. Some participants in both arms experienced ongoing disease activity, and the overall remission rates were modest, indicating that neither drug guarantees a symptom‑free state for all patients.

Safety profiles were comparable. Both medications were associated with infections, particularly of the respiratory or gastrointestinal tract, and rare cases of allergic reactions. No new safety signals emerged during the study, but longer follow‑up is needed to fully understand rare adverse events. How the results fit into current treatment options

Biologic therapy for Crohn's disease typically follows a sequence: anti‑TNF agents (such as infliximab or adalimumab) are often tried first, followed by agents that target interleukin‑12/23 (ustekinumab) or interleukin‑23 alone (risankizumab). The SEQUENCE data adds granularity to that algorithm.

• Patients who have failed an anti‑TNF agent may consider moving directly to an interleukin‑23 blocker, especially if they are concerned about the higher infection rates sometimes seen with anti‑TNF drugs.
• For individuals already on ustekinumab without sufficient improvement, switching to risankizumab could be a reasonable next step, based on the observed remission gap in the trial.
• Conversely, if a patient has contraindications to risankizumab - such as a history of certain autoimmune conditions - the modest benefit of ustekinumab might still be appropriate.

It's worth noting that real‑world practice often involves factors beyond trial numbers: patient preference, insurance coverage, route of administration (subcutaneous versus intravenous), and the presence of comorbidities all play a role in selecting therapy. Practical considerations for patients

If you are discussing biologic options with Dr. Sameer Idris or another gastroenterology specialist, you might ask about the following points:

• Effectiveness expectations: Explain that while risankizumab showed a higher remission rate in the SEQUENCE trial, many patients on both drugs still need additional treatment adjustments.
• Safety monitoring: Inquire about the schedule for blood tests and screenings for infections, especially tuberculosis, which are standard before starting any biologic.
• Administration logistics: Risankizumab is usually given as an injection every 12 weeks after an initial loading phase, whereas ustekinumab may require a combination of intravenous and subcutaneous dosing. Understanding the schedule can help you plan around work or travel.
• Insurance and cost: Both agents are covered under many health plans in the UAE, but prior authorization may be required. Ask the clinic staff to assist with paperwork.
• Future follow‑up: Ask how often endoscopic evaluation will be needed to assess remission, and whether non‑invasive markers (like fecal calprotectin) could reduce the frequency of colonoscopies.

Remember that treatment success is often measured by a combination of symptom relief, quality‑of‑life improvements, and objective healing seen on imaging or endoscopy. A single medication may not address all aspects, and combination approaches (dietary measures, lifestyle modifications, and adjunctive medication) remain an essential part of disease management. Key takeaways

• Risankizumab showed a higher endoscopic remission rate than ustekinumab in a 48‑week head‑to‑head trial.
• Both drugs carry similar infection‑related safety concerns; long‑term data are still emerging.
• The trial results can inform decisions after anti‑TNF failure, but individual factors may guide drug choice.
• Discuss administration schedule, monitoring plan, and insurance details with your clinician.
• Ongoing assessment of symptoms and objective disease markers is essential regardless of the biologic chosen.

Staying informed and maintaining an open dialogue with your gastroenterology team can help you navigate the complexities of Crohn's disease treatment. New research continues to shape the options available, and your clinician can tailor therapy to your specific situation.

This information is general and not a substitute for personalized medical advice. Please consult your own healthcare provider before making any changes to your treatment plan.